Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04) Meeting Abstract
| Authors: | Li, B. T.; Ahn, M. J.; Goto, K.; Mazieres, J.; Padda, S. K.; William, W. N.; Wu, Y. L.; Dearden, S.; Ragone, A.; Viglianti, N.; Gasco, A. |
| Abstract Title: | Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680305121 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.TPS9137 |
| Notes: | Meeting Abstract: TPS9137 -- Meeting also held virtually -- Source: Wos |
